Now I have a thorough understanding of the paper. Let me synthesize my review based on verified claims.

## Summary

GENOT introduces a neural entropic optimal transport framework that leverages conditional flow matching to learn the conditional distributions of EOT couplings. It unifies four OT settings—balanced/unbalanced Kantorovich, balanced/unbalanced Gromov-Wasserstein, and Fused GW—under a single method, with supporting theoretical results (Prop. 3.1: well-posedness; Prop. 3.2: re-balancing unbalanced problems into balanced ones; Prop. 3.3: consistent re-weighting estimation). The method handles arbitrary cost functions and maps across spaces of different dimensions, demonstrated in single-cell biology applications.

## Strengths

- **Cost-function agnosticism and cross-space mapping**: GENOT operates with any cost function—including non-differentiable ones like geodesic distances on k-nn graphs—and naturally handles source/target spaces of different dimensions by defining flows in the target domain. This differentiates it from Schrödinger bridge-based EOT solvers (Tong et al., 2023b; Shi et al., 2023; Liu et al., 2023), which are restricted to squared Euclidean cost and same-space settings. The geodesic cost advantage is demonstrated in Fig. 6 (ATAC→RNA translation) where the geodesic cost variant substantially outperforms Euclidean cost in higher dimensions.

- **Unified framework with theoretical grounding**: The paper is the first neural method to handle (Fused) GW entropic OT and unbalanced extensions within one conditional flow matching framework. Proposition 3.2 (re-balancing unbalanced problems into balanced ones over re-weighted marginals) is a non-trivial and useful theoretical result enabling U-GENOT. Proposition 3.1 provides well-posedness guarantees, and Proposition 3.3 establishes consistent estimation of re-weighting functions.

- **Practical unbalanced extension improves results**: The re-balancing approach yields concrete empirical gains. In drug perturbation (Fig. 3), U-GENOT-K improves prediction accuracy for 8 of 9 drugs compared to balanced GENOT-K. In Fig. 12, pancreas lineage accuracy improves from 66% to 82% when mass conservation is loosened. The FGW extension achieves FOSCTTM < 0.05 for ATAC→RNA translation (§5.2), substantially better than pure GW.

- **Non-trivial application contribution (FGW modality translation)**: The fused extension for ATAC→RNA translation, using gene activity as a bridge modality, is a meaningful and well-motivated application contribution that leverages the framework's flexibility (§3.3, Fig. 5).

## Weaknesses

### Fatal
None.

### Major
- **Weak experimental support for the GW-only setting, which is the most novel claim.** The paper's most distinctive contribution—being the first neural method for continuous (Fused) GW OT—has thin experimental backing. The GW-only experiment on simulated data (Swiss roll→spiral, §5.2, Fig. 4) is purely qualitative with no quantitative metric (e.g., GW cost of the learned coupling, isometry error). The real-data GW experiment (ATAC→RNA) shows that pure GENOT-GW performs poorly enough that the authors themselves state "predictions yielded by GW-based models are not satisfactory" (p. 255), motivating the Fused extension. Furthermore, no comparison is provided against Nekrashevich et al. (2023), which the paper itself identifies as the only existing neural GW method (p. 33). The FGW results are stronger but depend on domain-specific feature engineering (gene activity as bridge), not on the pure GW machinery. The core novelty of neural GW solving is thus inadequately validated.

### Minor
- **Overclaimed uncertainty quantification in the abstract.** The abstract claims the method provides "well-calibrated uncertainty estimation" for drug perturbation, but the cos-var uncertainty metric shows negative correlation with prediction error for all but one drug (§5.1, Fig. 1 right), meaning higher uncertainty coincides with lower error—the opposite of good calibration. The pancreas uncertainty visualization (Fig. 2) is biologically meaningful but qualitative. The stochasticity remains useful for modeling non-deterministic cell trajectories and computing conditional statistics, but the "well-calibrated" claim should be tempered.

- **No experimental comparison with SB-based EOT solvers on their common ground.** While GENOT's main differentiation is handling arbitrary costs and cross-space mapping (making SB methods incomparable in those settings), the pancreas and drug perturbation experiments use squared Euclidean cost, where SB-based methods (Tong et al., 2023a;b; Shi et al., 2023; Liu et al., 2023) are applicable. A comparison with at least one such method on the Kantorovich tasks would validate that GENOT-K achieves competitive performance in the shared regime, strengthening the overall empirical case.

- **Conditionally positive kernel assumption for U-GENOT-GW not verified experimentally.** Proposition 3.2's claim 2 requires the intra-domain costs to be conditionally positive (or negative) kernels (Def. B.1). The paper does not discuss whether this assumption holds for the geodesic cost used in the ATAC→RNA experiments, which matters for the validity of the re-balancing result in the GW case.

### Trivial
None significant.

## Nice-to-Haves
- Quantitative evaluation of the Swiss roll→spiral experiment (e.g., GW cost, isometry error) to complement the visual assessment.
- Ablation studying the impact of mini-batch size and ε on coupling quality to characterize the practical effects of mini-batch bias.
- Diagnosis of why uncertainty quantification fails in the drug perturbation setting and conditions under which it succeeds.

## Removed Points

- **"Missing appendix/proofs"**: The parser strips appendix sections from all papers; these exist in the original submission. Removed per rules.

- **"Not yet released / cannot be independently verified" for any cited model, method, or dataset**: Per hard rules, all cited entities are assumed to exist and be available. This includes Nekrashevich et al. (2023). Removed.

- **Demand for comparisons with methods that would be disadvantaged as baselines**: The paper's Kantorovich experiments use CFM and Monge map estimators as baselines, which are simpler/deterministic methods. While SB-based methods would be relevant additional baselines, the current baselines are not unfairly selected. The suggestion to add SB baselines is kept as a minor weakness/nice-to-have, not treated as a fatal omission.

- **Formatting and typography complaints**: Removed per rules.

- **Nitpicks about reproducibility (undisclosed hyperparameters, etc.)**: The paper provides algorithm descriptions; minor implementation details are standard to omit. Removed.

- **Generic strength "this paper addressed an important problem"**: Dropped as it is non-specific.

- **Generic strength claims about "valuable in single-cell biology"**: The abstract claims GENOT "proves valuable" in single-cell biology; this is partially undermined by the weak GW results and uncalibrated uncertainty. Kept the specific, evidence-backed application strength (FGW modality translation) while dropping the generic claim.

## Novel Insights

The paper's most insightful observation is that the re-balancing trick (Prop. 3.2) converts unbalanced OT problems—which arise naturally in single-cell biology due to differential proliferation rates and experimental biases—into balanced ones over re-weighted marginals, enabling the use of standard balanced EOT solvers. This is not just a theoretical convenience; the lineage accuracy improvement from 66% to 82% in the pancreas experiment shows practical impact. However, a tension in the paper is that the stochasticity selling point is stronger as a modeling choice (non-deterministic cell trajectories, conditional statistics) than as an uncertainty quantification tool, given the cos-var failure in drug perturbation.

## Suggestions

- Add a quantitative metric to the Swiss roll→spiral GW experiment and compare against Nekrashevich et al. (2023) on at least one GW benchmark, to substantiate the core novel claim.
- Temper the "well-calibrated uncertainty estimation" claim in the abstract to reflect the mixed empirical evidence; the stochasticity advantage is better framed as enabling biological trajectory modeling and conditional statistics rather than guarantees of calibrated uncertainty.
- For the ATAC→RNA task, discuss why pure GW fails (e.g., ill-posedness of the matching problem without inter-domain cost information) and what this implies practically for GENOT-GW usage.

## Evaluation

**Originality**: The paper makes a genuine contribution by providing the first neural EOT framework that handles GW, FGW, and unbalanced extensions under one method, with the re-balancing result (Prop. 3.2) being a non-trivial theoretical insight. The cost-agnostic cross-space approach is structurally novel relative to SB-based methods.

**Importance of research question**: Mapping distributions across spaces with flexible costs is important for single-cell biology and beyond. The unbalanced formulation addresses real practical needs.

**Claims well supported**: Partially. The Kantorovich and FGW settings are reasonably supported. The GW-only claim—the most novel—is inadequately validated. The uncertainty quantification claim is overclaimed. The theoretical framework is sound.

**Soundness of experiments**: Experiments demonstrate the framework's flexibility and the FGW application works well. The GW-only validation is thin (qualitative toy example + poor real-data performance). Missing baselines (Nekrashevich et al. for GW; SB methods for Kantorovich) weaken the empirical case.

**Clarity**: The paper is well-organized, progressing cleanly from theory to experiments. The notation is standard for the field.

**Value**: The framework is broadly applicable and the code would be a useful tool for the community. The FGW application demonstrates genuine utility.

MY FINAL SCORE: <pineapple>5.5</pineapple>
MY FINAL DECISION: <orange>Accept</orange>